AF-driven expansion of CD14 + HLA-DR -/low MDSC was dependent on IL-6/IL10-STAT3 signal pathway PBMC from HD (n = 3) were treated with the AF (50% v/v) from OC patients (n=4) in the presence of neutralizing antibodies against IL-6 and/or IL-10 (A) or STAT3 inhibitor stattic (B) for 48 hours and then analyzed for the abundance of CD14 + HLA-DR -/low MDSC by flow cytometry. Addition of isotype antibody or DMSO was as controls. The representative dotplots were shown in left panel and the statistics were shown in right graph. The data are expressed as mean ± SEM of 4 biological replicates and representative of three independent experiments. *p